Biogen Inc (IDP.BE)
Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
At close: 08:21PM CEST
| Previous close | 210.80 |
| Open | 210.70 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 208.30 - 212.70 |
| 52-week range | 177.95 - 266.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 23 July 2024 - 29 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksIonis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
ZacksAlzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
ZacksThe Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.
© 2024 Yahoo. All rights reserved.